Combining innovative science, leading technology, and unmatched know-how to create novel medicines.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Our Science
Our lead program targets interleukin-11, a cytokine which is a central mediator of fibrosis.
Our Pipeline
Lassen is applying industry-leading antibody technologies to create a pipeline of breakthrough therapeutics.
Our team has a proven track record of building robust antibody development platforms and pipelines and is guided by a set of meaningful and inspirational core values. We are:
- Innovative and adapt to challenges
- Honest and communicate transparently
- Collaborative and treat everyone with respect
- Focused on people – our team, our collaborators, and patients
- Passionate about creating life-improving medicines
-
- Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease
-
- LASN01, a fully human, clinical-stage antibody which binds to IL-11R, potently blocks IL-11 signaling to prevent IL-11 driven fibrotic diseases
-
- Inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis and other fibro-inflammatory diseases